肌少症與晚期肝細胞癌預後相關性文獻分析

10.6666/ClinMed.202102_87(2).0018

鄭琮譯；李沛璋；黃怡翔；侯明志

肌少症（sarcopenia） ； 蕾莎瓦（sorafenib） ； 晚期肝癌（advanced hepatocellular carcinoma）

臨床醫學月刊

87卷2期（2021 / 02 / 26）

119 - 122

繁體中文

過去陸續有研究發現：肌少症對於肝硬化及肝癌患者的預後有明顯的相關性。本文就肌少症的診斷方式、在肝癌中的盛行率及預後影響做文獻的整理，並且探討營養補充及維持肌肉質量，對於延長高危險患者的存活之可能性。

1. Abou-Alfa, GK,Meyer, T,Cheng, AL(2018).Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma.N Engl J Med,379,54-63.
2. Antonelli, G,Gigante, E,Iavarone, M(2018).Sarcopenia is associated with reduced survival in patients with advanced hepatocellular carcinoma undergoing sorafenib treatment.United European Gastroenterol J,6,1039-1048.
3. Bruggeman, AR,Kamal, AH,LeBlanc, TW(2016).Cancer Cachexia: Beyond Weight Loss.J Oncol Pract,12,1163-1171.
4. Bruix, J,Qin, S,Merle, P(2017).Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet,389,56-66.
5. Chen, LK,Liu, LK,Woo, J(2014).Sarcopenia in Asia: consensus report of the Asian Working Group for Sarcopenia.J Am Med Dir Assoc,15,95-101.
6. Cheng, AL,Kang, YK,Chen, Z(2009).Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.Lancet Oncol,10,25-34.
7. Cruz-Jentoft, AJ,Baeyens, JP,Bauer, JM(2010).Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People.Age Ageing,39,412-423.
8. Durand, F,Buyse, S,Francoz, C(2014).Prognostic value of muscle atrophy in cirrhosis using psoas muscle thickness on computed tomography.J Hepatol,60,1151-1157.
9. European Association for the Study of the Liver(2019).EASL Clinical Practice Guidelines on nutrition in chronic liver disease.J Hepatol,70,172-193.
10. European Association for the Study of the Liver(2018).Electronic address eee, European Association for the Study of the L. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma.J Hepatol,69,182-236.
11. Gu, DH,Kim, MY,Seo, YS(2018).Clinical usefulness of psoas muscle thickness for the diagnosis of sarcopenia in patients with liver cirrhosis.Clin Mol Hepatol,24,319-330.
12. Hanai, T,Shiraki, M,Ohnishi, S(2016).Rapid skeletal muscle wasting predicts worse survival in patients with liver cirrhosis.Hepatol Res,46,743-751.
13. Hiraoka, A,Hirooka, M,Koizumi, Y(2017).Muscle volume loss as a prognostic marker in hepatocellular carcinoma patients treated with sorafenib.Hepatol Res,47,558-565.
14. Imai, K,Takai, K,Hanai, T(2015).Skeletal muscle depletion predicts the prognosis of patients with hepatocellular carcinoma treated with sorafenib.Int J Mol Sci,16,9612-9624.
15. Imai, K,Takai, K,Watanabe, S(2017).Sarcopenia Impairs Prognosis of Patients with Hepatocellular Carcinoma: The Role of Liver Functional Reserve and Tumor-Related Factors in Loss of Skeletal Muscle Volume.Nutrients,9,pii:E1054.
16. Iritani, S,Imai, K,Takai, K(2015).Skeletal muscle depletion is an independent prognostic factor for hepatocellular carcinoma.J Gastroenterol,50,323-332.
17. Lee, PC,Chen, YT,Chao, Y(2018).Validation of the albumin-bilirubin grade-based integrated model as a predictor for sorafenib-failed hepatocellular carcinoma.Liver Int,38,321-330.
18. Merli, M,Riggio, O,Dally, L(1996).Does malnutrition affect survival in cirrhosis? PINC (Policentrica Italiana Nutrizione Cirrosi).Hepatology,23,1041-1046.
19. Mir, O,Coriat, R,Blanchet, B(2012).Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma.PLoS One,7,e37563.
20. Nishikawa, H,Nishijima, N,Enomoto, H(2017).Prognostic significance of sarcopenia in patients with hepatocellular carcinoma undergoing sorafenib therapy.Oncol Lett,14,1637-1647.
21. Njei, B,Rotman, Y,Ditah, I(2015).Emerging trends in hepatocellular carcinoma incidence and mortality.Hepatology,61,191-199.
22. Palmer, DH(2008).Sorafenib in advanced hepatocellular carcinoma.N Engl J Med,359,2497-2499.
23. Prado, CM,Lieffers, JR,McCargar, LJ(2008).Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study.Lancet Oncol,9,629-635.
24. Praktiknjo, M,Book, M,Luetkens, J(2018).Fat-free muscle mass in magnetic resonance imaging predicts acute-on-chronic liver failure and survival in decompensated cirrhosis.Hepatology,67,1014-1026.
25. Riggio, O,Angeloni, S,Ciuffa, L(2003).Malnutrition is not related to alterations in energy balance in patients with stable liver cirrhosis.Clin Nutr,22,553-559.
26. Rosenberg, IH(2011).Sarcopenia: origins and clinical relevance.Clin Geriatr Med,27,337-339.
27. Schutte, K,Tippelt, B,Schulz, C(2015).Malnutrition is a prognostic factor in patients with hepatocellular carcinoma (HCC).Clin Nutr,34,1122-1127.
28. Takeda, H,Nishikawa, H,Iguchi, E(2014).Effect of treatment with branched-chain amino acids during sorafenib therapy for unresectable hepatocellular carcinoma.Hepatol Res,44,302-312.
29. Tan, BH,Birdsell, LA,Martin, L(2009).Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer.Clin Cancer Res,15,6973-6979.
30. Zhu, AX,Kang, YK,Yen, CJ(2019).Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet Oncol,20,282-296.